Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs ACTIFED W/ CODEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; triprolidine is an H1 receptor antagonist. The combination produces antitussive and antihistamine effects.
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Symptomatic relief of cough and upper respiratory symptoms associated with allergy or cold
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Adults: 10 m L orally every 4-6 hours as needed, not to exceed 4 doses in 24 hours. Each 10 m L contains 10 mg codeine, 4 mg triprolidine, 60 mg pseudoephedrine.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Codeine: 2.5-4 hours; pseudoephedrine: 5-8 hours; triprolidine: 3-6 hours. Context: Codeine half-life prolonged in hepatic impairment and CYP2D6 poor metabolizers; pseudoephedrine half-life increased with alkaline urine.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Codeine is metabolized primarily via glucuronidation and O-demethylation to morphine by CYP2D6, and N-demethylation to norcodeine by CYP3A4. Triprolidine is metabolized by hepatic CYP450 enzymes.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Renal: 60-80% (codeine and metabolites, primarily as codeine-6-glucuronide, norcodeine, and morphine); unchanged codeine <10%. Fecal: <10%. Biliary: minor.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Codeine: 7-25% (primarily albumin); pseudoephedrine: negligible (<5%); triprolidine: approximately 85% (mainly albumin).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Codeine: 3-6 L/kg; pseudoephedrine: 2.5-3.5 L/kg; triprolidine: 2-5 L/kg. Indicates extensive tissue distribution.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Codeine: 50-70% (oral); pseudoephedrine: 100% (oral); triprolidine: approximately 50% (oral) due to first-pass metabolism.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
GFR 30-59 m L/min: administer every 6 hours; GFR <30 m L/min: administer every 12 hours or avoid use due to risk of accumulation of codeine and pseudoephedrine; hemodialysis: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Child-Pugh A (mild): no adjustment; Child-Pugh B (moderate): reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C (severe): avoid use due to risk of central nervous system depression.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Not recommended in children <12 years due to risk of respiratory depression. For children ≥12 years: 10 m L orally every 4-6 hours as needed, max 4 doses in 24 hours. Weight-based dosing not established.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Start at lower dose (e.g., 5 m L orally every 6 hours) due to increased sensitivity to anticholinergic and sedative effects; monitor for confusion, urinary retention, and hypotension.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYP2D6 GENETIC VARIABILITY; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE OF CYP3A4 INHIBITORS; RISKS IN PATIENTS WITH GASTROINTESTINAL CONDITIONS; RISKS OF USE IN PATIENTS WITH ASTHMA OR OTHER RESPIRATORY DISEASE; LABEL FOR INFANTS AND CHILDREN.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,CYP2D6 genetic variability (ultrarapid metabolizers),Accidental ingestion,Interaction with alcohol,Use in patients with gastrointestinal conditions,Use in patients with asthma or other respiratory disease,Avoid use in children <12 years
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Hypersensitivity to codeine, triprolidine, or any component,Children <12 years,Postoperative management in children <18 years after tonsillectomy and/or adenoidectomy,Significant respiratory depression,Acute or severe bronchial asthma,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days,Paralytic ileus,Known CYP2D6 ultrarapid metabolizers
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
Avoid grapefruit and grapefruit juice as they may increase codeine levels and risk of adverse effects. High-tyramine foods (aged cheese, cured meats, fermented products) may interact with pseudoephedrine, potentially causing hypertensive crisis. Alcohol is contraindicated due to additive CNS depression.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
First trimester: Codeine is associated with increased risk of congenital malformations (OR 1.24–2.0), particularly cardiac defects, with a dose-response relationship. Triprolidine and pseudoephedrine are generally considered low risk, but pseudoephedrine may be associated with gastroschisis (OR 1.8). Second trimester: Codeine may cause fetal dependence; pseudoephedrine may reduce uteroplacental blood flow. Third trimester: Codeine can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery; pseudoephedrine may exacerbate pregnancy-induced hypertension. Overall, avoid in pregnancy for non-severe indications.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Codeine and pseudoephedrine are excreted into breast milk. M/P ratio for codeine is ~2.5; for pseudoephedrine, ~2.6–3.5. Use is contraindicated in breastfeeding due to risk of neonatal opioid toxicity (especially in CYP2D6 ultra-rapid metabolizers) and potential irritability/poor feeding from pseudoephedrine. Triprolidine has limited data but is considered compatible in low doses.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
No specific dose adjustments are established; however, due to increased renal clearance of pseudoephedrine in pregnancy, standard doses may be less effective. Codeine metabolism via CYP2D6 is variably affected by pregnancy (increased clearance ≈30–50% in second/third trimester), potentially requiring dose titration. Avoid use entirely in pregnancy; use alternative agents if needed.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Actifed w/ Codeine combines triprolidine, pseudoephedrine, and codeine. Due to codeine's prodrug metabolism via CYP2D6, ultra-rapid metabolizers risk toxicity; contraindicated in children <12 years, post-tonsillectomy/adenoidectomy, and breastfeeding. Pseudoephedrine may cause hypertensive crisis with MAOIs. Triprolidine's anticholinergic effects exacerbate glaucoma, urinary retention, and cognitive impairment in elderly.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
Do not exceed recommended dose; risk of serious breathing problems, especially in children.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Store securely; codeine carries risk of dependence and misuse.,If pregnant or breastfeeding, consult prescriber; do not use while breastfeeding due to infant toxicity risk.,May cause drowsiness; avoid driving or operating heavy machinery until effects are known.,Inform healthcare provider of all medications, especially MAOIs (within 14 days), antidepressants, or blood pressure medications.,Discontinue and seek medical help if symptoms of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing) occur.,Use caution with high blood pressure, thyroid problems, diabetes, or enlarged prostate.
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs ACTIFED W/ CODEINE, answered by our medical review team.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. ACTIFED W/ CODEINE is a Opioid Agonist that works by Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; triprolidine is an H1 receptor antagonist. The combination produces antitussive and antihistamine effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and ACTIFED W/ CODEINE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of ACTIFED W/ CODEINE is: Adults: 10 m L orally every 4-6 hours as needed, not to exceed 4 doses in 24 hours. Each 10 m L contains 10 mg codeine, 4 mg triprolidine, 60 mg pseudoephedrine.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and ACTIFED W/ CODEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. ACTIFED W/ CODEINE is classified as Category D/X. First trimester: Codeine is associated with increased risk of congenital malformations (OR 1.24–2.0), particularly cardiac defects, with a dose-response relationship. Triprolidine . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.